Posted by Michael Wonder on 12 Dec 2024
ICER announces most significant drug price hikes unsupported by new clinical evidence in US
12 December 2024 - Of 10 high expenditure drugs that had substantial 2023 net price increases, five were not supported by new clinical evidence; these increases accounted for $815 million in additional costs over one year.
The ICER today published its latest report on unsupported price increases of prescription drugs in the US, highlighting the top 10 drugs with substantial net price increases in 2023. ICER determined that five of those drugs lacked adequate evidence to support any price increase, which resulted in a total of $815 million incremental added costs to US payers in 2023. The five drugs with unsupported price increases are Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz.
